Generic placeholder image

Current Drug Targets

Author(s): Erica Martins Ferreira Gotardo, Thaina Rodrigues de Morais, Ana Paula Timóteo Ferreira, Cintia Rabelo e Paiva Caria, Marcelo Lima Ribeiro and Alessandra Gambero*

DOI: 10.2174/1389450124666230602110705

DownloadDownload PDF Flyer Cite As
Deferoxamine Interference in Fibro-inflammation: Additional Action in Control of Obese Adipose Tissue Dysfunction

Page: [688 - 696] Pages: 9

  • * (Excluding Mailing and Handling)

Abstract

Introduction: Several studies demonstrated that deferoxamine, an iron chelator, can improve inflammatory alterations in adipose tissue induced by obesity. Obesity alterations in adipose tissue are also associated with tissue remodeling, and deferoxamine has anti-fibrosis action previously described in sites like the skin and liver.

Methods: In this work, we analyzed deferoxamine effects on adipose tissue fibro-inflammation during obesity induced by diet in mice. in vitro approaches with fibroblasts and macrophages were also carried out to elucidate deferoxamine activity.

Results: Our results demonstrated that in addition to exerting anti-inflammatory effects, reducing the cytokine production in adipose tissue of obese mice and by human monocyte differentiated in macrophage in vitro, deferoxamine can alter metalloproteinases expression and extracellular matrix production in vivo and in vitro.

Conclusion: Deferoxamine could be an alternative to control fibro-inflammation in obese adipose tissue, contributing to the metabolic improvements previously described.

Graphical Abstract

[1]
Entezari S, Haghi SM, Norouzkhani N, et al. Iron Chelators in Treatment of Iron Overload. J Toxicol 2022; 2022: 1-18.
[http://dx.doi.org/10.1155/2022/4911205] [PMID: 35571382]
[2]
Tajima S, Ikeda Y, Sawada K, et al. Iron reduction by deferoxamine leads to amelioration of adiposity via the regulation of oxidative stress and inflammation in obese and type 2 diabetes KKAy mice. Am J Physiol Endocrinol Metab 2012; 302(1): E77-86.
[http://dx.doi.org/10.1152/ajpendo.00033.2011] [PMID: 21917632]
[3]
Yan HF, Liu ZY, Guan ZA, Guo C. Deferoxamine ameliorates adipocyte dysfunction by modulating iron metabolism in ob/ob mice. Endocr Connect 2018; 7(4): 604-16.
[http://dx.doi.org/10.1530/EC-18-0054] [PMID: 29678877]
[4]
Moreno-Navarrete JM, Ortega F, Moreno M, Ricart W, Fernández-Real JM. Fine-tuned iron availability is essential to achieve optimal adipocyte differentiation and mitochondrial biogenesis. Diabetologia 2014; 57(9): 1957-67.
[http://dx.doi.org/10.1007/s00125-014-3298-5] [PMID: 24973963]
[5]
Wree A, Mayer A, Westphal S, et al. Adipokine expression in brown and white adipocytes in response to hypoxia. J Endocrinol Invest 2012; 35(5): 522-7.
[PMID: 21952510]
[6]
Oses C, Olivares B, Ezquer M, et al. Preconditioning of adipose tissue-derived mesenchymal stem cells with deferoxamine increases the production of pro-angiogenic, neuroprotective and anti-inflammatory factors: Potential application in the treatment of diabetic neuropathy. PLoS One 2017; 12(5): e0178011.
[http://dx.doi.org/10.1371/journal.pone.0178011] [PMID: 28542352]
[7]
Marcelin G, Clément K. The multifaceted progenitor fates in healthy or unhealthy adipose tissue during obesity. Rev Endocr Metab Disord 2021; 22(4): 1111-9.
[http://dx.doi.org/10.1007/s11154-021-09662-0] [PMID: 34105090]
[8]
Bel Lassen P, Charlotte F, Liu Y, et al. The FAT Score, a Fibrosis Score of Adipose Tissue: Predicting Weight-Loss Outcome After Gastric Bypass. J Clin Endocrinol Metab 2017; 102(7): 2443-53.
[http://dx.doi.org/10.1210/jc.2017-00138] [PMID: 28419237]
[9]
Caria CRP, Gotardo ÉMF, Santos PS, et al. Extracellular matrix remodeling and matrix metalloproteinase inhibition in visceral adipose during weight cycling in mice. Exp Cell Res 2017; 359(2): 431-40.
[http://dx.doi.org/10.1016/j.yexcr.2017.08.026] [PMID: 28826677]
[10]
Ali MK, Kim RY, Brown AC, et al. Critical role for iron accumulation in the pathogenesis of fibrotic lung disease. J Pathol 2020; 251(1): 49-62.
[http://dx.doi.org/10.1002/path.5401] [PMID: 32083318]
[11]
Shen AH, Borrelli MR, Adem S, et al. Prophylactic treatment with transdermal deferoxamine mitigates radiation-induced skin fibrosis. Sci Rep 2020; 10(1): 12346.
[http://dx.doi.org/10.1038/s41598-020-69293-4] [PMID: 32704071]
[12]
Mehta KJ, Coombes JD, Briones-Orta M, et al. Iron Enhances Hepatic Fibrogenesis and Activates Transforming Growth Factor-β Signaling in Murine Hepatic Stellate Cells. Am J Med Sci 2018; 355(2): 183-90.
[http://dx.doi.org/10.1016/j.amjms.2017.08.012] [PMID: 29406047]
[13]
Candida DeOliveira C, Coghetto Acedo S, Martins Ferreira Gotardo É, et al. Effects of methotrexate on inflammatory alterations induced by obesity: An in vivo and in vitro study. Mol Cell Endocrinol 2012; 361(1-2): 92-8.
[http://dx.doi.org/10.1016/j.mce.2012.03.016] [PMID: 22480543]
[14]
DeOliveira CC, Paiva Caria CR, Ferreira Gotardo EM, Ribeiro ML, Gambero A. Role of A1 and A2A adenosine receptor agonists in adipose tissue inflammation induced by obesity in mice. Eur J Pharmacol 2017; 799: 154-9.
[http://dx.doi.org/10.1016/j.ejphar.2017.02.017] [PMID: 28202393]
[15]
Santos J, Gotardo É, Brianti M, Piraee M, Gambero A, Ribeiro M. Effects of yerba maté, a plant extract formulation (“YGD”) and resveratrol in 3T3-L1 adipogenesis. Molecules 2014; 19(10): 16909-24.
[http://dx.doi.org/10.3390/molecules191016909] [PMID: 25338179]
[16]
Macedo JA, Ferreira LR, Camara LE, et al. Chemopreventive potential of the tannase-mediated biotransformation of green tea. Food Chem 2012; 133(2): 358-65.
[http://dx.doi.org/10.1016/j.foodchem.2012.01.041] [PMID: 25683407]
[17]
Acedo SC, Gambero S, Cunha FGP, Lorand-Metze I, Gambero A. Participation of leptin in the determination of the macrophage phenotype: An additional role in adipocyte and macrophage crosstalk. in vitro Cell Dev Biol Anim 2013; 49(6): 473-8.
[http://dx.doi.org/10.1007/s11626-013-9629-x] [PMID: 23708919]
[18]
Jing X, Du T, Yang X, et al. Desferoxamine protects against glucocorticoid-induced osteonecrosis of the femoral head via activating HIF-1α expression. J Cell Physiol 2020; 235(12): 9864-75.
[http://dx.doi.org/10.1002/jcp.29799] [PMID: 32437020]
[19]
Holden P, Nair LS. Deferoxamine: An Angiogenic and Antioxidant Molecule for Tissue Regeneration. Tissue Eng Part B Rev 2019; 25(6): 461-70.
[http://dx.doi.org/10.1089/ten.teb.2019.0111] [PMID: 31184273]
[20]
Li Y, Pan K, Chen L, et al. Deferoxamine regulates neuroinflammation and iron homeostasis in a mouse model of postoperative cognitive dysfunction. J Neuroinflammation 2016; 13(1): 268.
[http://dx.doi.org/10.1186/s12974-016-0740-2] [PMID: 27733186]
[21]
Zeinivand M, Nahavandi A, Zare M. Deferoxamine regulates neuroinflammation and oxidative stress in rats with diabetes-induced cognitive dysfunction. Inflammopharmacology 2020; 28(2): 575-83.
[http://dx.doi.org/10.1007/s10787-019-00665-7] [PMID: 31786804]
[22]
Lavin CV, Abbas DB, Fahy EJ, et al. A comparative analysis of deferoxamine treatment modalities for dermal radiation-induced fibrosis. J Cell Mol Med 2021; 25(21): 10028-38.
[http://dx.doi.org/10.1111/jcmm.16913] [PMID: 34612609]
[23]
Marcelin G, Ferreira A, Liu Y, et al. A PDGFRα-Mediated Switch toward CD9high Adipocyte Progenitors Controls Obesity-Induced Adipose Tissue Fibrosis. Cell Metab 2017; 25(3): 673-85.
[http://dx.doi.org/10.1016/j.cmet.2017.01.010] [PMID: 28215843]
[24]
Keophiphath M, Achard V, Henegar C, Rouault C, Clément K, Lacasa D. Macrophage-secreted factors promote a profibrotic phenotype in human preadipocytes. Mol Endocrinol 2009; 23(1): 11-24.
[http://dx.doi.org/10.1210/me.2008-0183] [PMID: 18945811]
[25]
Reggio S, Rouault C, Poitou C, et al. Increased Basement Membrane Components in Adipose Tissue During Obesity: Links With TGFβ and Metabolic Phenotypes. J Clin Endocrinol Metab 2016; 101(6): 2578-87.
[http://dx.doi.org/10.1210/jc.2015-4304] [PMID: 27049236]
[26]
Lee MJ. Transforming growth factor beta superfamily regulation of adipose tissue biology in obesity. Biochim Biophys Acta Mol Basis Dis 2018; 1864(4) (4 Pt A): 1160-71.
[http://dx.doi.org/10.1016/j.bbadis.2018.01.025] [PMID: 29409985]
[27]
Sousa-Pinto B, Gonçalves L, Rodrigues AR, et al. Characterization of TGF-β expression and signaling profile in the adipose tissue of rats fed with high-fat and energy-restricted diets. J Nutr Biochem 2016; 38: 107-15.
[http://dx.doi.org/10.1016/j.jnutbio.2016.07.017] [PMID: 27736730]
[28]
Divoux A, Tordjman J, Lacasa D, et al. Fibrosis in human adipose tissue: Composition, distribution, and link with lipid metabolism and fat mass loss. Diabetes 2010; 59(11): 2817-25.
[http://dx.doi.org/10.2337/db10-0585] [PMID: 20713683]
[29]
Spencer M, Unal R, Zhu B, et al. Adipose tissue extracellular matrix and vascular abnormalities in obesity and insulin resistance. J Clin Endocrinol Metab 2011; 96(12): E1990-8.
[http://dx.doi.org/10.1210/jc.2011-1567] [PMID: 21994960]
[30]
Ruiz-Ojeda FJ, Méndez-Gutiérrez A, Aguilera CM, Plaza-Díaz J. Extracellular Matrix Remodeling of Adipose Tissue in Obesity and Metabolic Diseases. Int J Mol Sci 2019; 20(19): 4888.
[http://dx.doi.org/10.3390/ijms20194888] [PMID: 31581657]
[31]
DeBari MK, Abbott RD. Adipose Tissue Fibrosis: Mechanisms, Models, and Importance. Int J Mol Sci 2020; 21(17): 6030.
[http://dx.doi.org/10.3390/ijms21176030] [PMID: 32825788]
[32]
Khan T, Muise ES, Iyengar P, et al. Metabolic dysregulation and adipose tissue fibrosis: role of collagen VI. Mol Cell Biol 2009; 29(6): 1575-91.
[http://dx.doi.org/10.1128/MCB.01300-08] [PMID: 19114551]
[33]
Traurig MT, Permana PA, Nair S, Kobes S, Bogardus C, Baier LJ. Differential expression of matrix metalloproteinase 3 (MMP3) in preadipocytes/stromal vascular cells from nonobese nondiabetic versus obese nondiabetic Pima Indians. Diabetes 2006; 55(11): 3160-5.
[http://dx.doi.org/10.2337/db06-0373] [PMID: 17065356]
[34]
Chun TH, Inoue M, Morisaki H, et al. Genetic link between obesity and MMP14-dependent adipogenic collagen turnover. Diabetes 2010; 59(10): 2484-94.
[http://dx.doi.org/10.2337/db10-0073] [PMID: 20660624]
[35]
Lijnen HR, Van Hoef B, Rodriguez JA, Paramo JA. Stromelysin-2 (MMP-10) deficiency does not affect adipose tissue formation in a mouse model of nutritionally induced obesity. Biochem Biophys Res Commun 2009; 389(2): 378-81.
[http://dx.doi.org/10.1016/j.bbrc.2009.08.170] [PMID: 19732744]
[36]
Rodrigues de Morais T, Gambero A. Iron chelators in obesity therapy – Old drugs from a new perspective? Eur J Pharmacol 2019; 861: 172614.
[http://dx.doi.org/10.1016/j.ejphar.2019.172614] [PMID: 31421090]
[37]
Wang S, Liu C, Pan S, et al. Deferoxamine attenuates lipopolysaccharide-induced inflammatory responses and protects against endotoxic shock in mice. Biochem Biophys Res Commun 2015; 465(2): 305-11.
[http://dx.doi.org/10.1016/j.bbrc.2015.08.032] [PMID: 26277391]
[38]
Zhang XY, Cao JB, Zhang LM, Li YF, Mi WD. Deferoxamine attenuates lipopolysaccharide-induced neuroinflammation and memory impairment in mice. J Neuroinflammation 2015; 12(1): 20.
[http://dx.doi.org/10.1186/s12974-015-0238-3] [PMID: 25644393]
[39]
Altamura S, Müdder K, Schlotterer A, et al. Iron aggravates hepatic insulin resistance in the absence of inflammation in a novel db/db mouse model with iron overload. Mol Metab 2021; 51: 101235.
[http://dx.doi.org/10.1016/j.molmet.2021.101235] [PMID: 33872860]